MA34652B1 - Hétéroaryles et utilisations de ceux-ci - Google Patents

Hétéroaryles et utilisations de ceux-ci

Info

Publication number
MA34652B1
MA34652B1 MA35882A MA35882A MA34652B1 MA 34652 B1 MA34652 B1 MA 34652B1 MA 35882 A MA35882 A MA 35882A MA 35882 A MA35882 A MA 35882A MA 34652 B1 MA34652 B1 MA 34652B1
Authority
MA
Morocco
Prior art keywords
heteroarylates
compounds
pi3k
mtor
inflammatory
Prior art date
Application number
MA35882A
Other languages
English (en)
Inventor
Brian S Freeze
Masaaki Hirose
Hong Myung Lee
Todd B Sells
Zhan Shi
Leo R Takaoka
Stepan Vyskocil
Tianlin Xu
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45938970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34652(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA34652B1 publication Critical patent/MA34652B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE I-A OU I-B : DANS LESQUELS HY, G1, G2, R2, R12, W1, W2, N, ET LE CYCLE A SONT TELS QUE DÉCRITS DANS LA DESCRIPTION. LES COMPOSÉS SONT DES INHIBITEURS DE PI3K ET/OU MTOR ET SONT PAR CONSÉQUENT UTILES POUR TRAITER DES TROUBLES PROLIFÉRATIFS, INFLAMMATOIRES, OU CARDIOVASCULAIRES.
MA35882A 2010-10-13 2013-05-06 Hétéroaryles et utilisations de ceux-ci MA34652B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39251510P 2010-10-13 2010-10-13
PCT/US2011/056135 WO2012051410A2 (fr) 2010-10-13 2011-10-13 Hétéroaryles et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA34652B1 true MA34652B1 (fr) 2013-11-02

Family

ID=45938970

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35882A MA34652B1 (fr) 2010-10-13 2013-05-06 Hétéroaryles et utilisations de ceux-ci

Country Status (24)

Country Link
US (2) US8765746B2 (fr)
EP (1) EP2627181A4 (fr)
JP (1) JP2013542941A (fr)
KR (1) KR20140091462A (fr)
CN (1) CN103237450A (fr)
AR (1) AR083450A1 (fr)
AU (1) AU2011316016A1 (fr)
BR (1) BR112013009166A2 (fr)
CA (1) CA2814688A1 (fr)
CL (1) CL2013001009A1 (fr)
CO (1) CO6801713A2 (fr)
CR (1) CR20130204A (fr)
DO (1) DOP2013000082A (fr)
EA (1) EA201390539A1 (fr)
EC (1) ECSP13012621A (fr)
IL (1) IL225607A0 (fr)
MA (1) MA34652B1 (fr)
MX (1) MX2013004003A (fr)
PE (1) PE20141044A1 (fr)
PH (1) PH12013500723A1 (fr)
SG (1) SG189396A1 (fr)
TW (1) TW201307309A (fr)
UY (1) UY33671A (fr)
WO (1) WO2012051410A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009094224A1 (fr) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophènes et leurs utilisations
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (fr) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryles et applications associees
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
PH12013500274A1 (en) 2010-08-11 2013-03-04 Millennium Pharm Inc Heteroaryls and uses thereof
CN103467481B (zh) * 2012-06-07 2016-08-31 上海汇伦生命科技有限公司 二氢吡啶类化合物、其组合物、制备方法和用途
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
EP4086259A1 (fr) 2015-11-06 2022-11-09 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
WO2017120194A1 (fr) 2016-01-05 2017-07-13 Incyte Corporation Pyridine et utilisation de composés de la pyridimine comme inhibiteurs de pi3k-gamma
WO2017223414A1 (fr) 2016-06-24 2017-12-28 Incyte Corporation Composants hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-y
US11236128B2 (en) 2017-07-31 2022-02-01 Agency For Science, Technology And Research Method of preparing stapled peptides
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN110041349B (zh) * 2019-05-15 2021-06-01 湖南科技大学 一种含螺二氢嘧啶衍生物及其制备方法和应用
KR102936514B1 (ko) 2019-06-06 2026-03-09 허치메드 리미티드 트리사이클릭 화합물 및 이의 용도
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL242505A (fr) 1958-08-20
US3852293A (en) 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
US3821384A (en) 1972-10-06 1974-06-28 Uniroyal Inc Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same
DE3021590A1 (de) 1980-06-09 1981-12-17 Hoechst Ag, 6000 Frankfurt 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998008845A1 (fr) 1996-08-27 1998-03-05 Novartis Ag 1,2,4,6-thiatriazines s-substituees desherbantes
JPH1087490A (ja) 1996-09-10 1998-04-07 Sagami Chem Res Center インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物
PT853083E (pt) 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
BR9804865B1 (pt) 1997-04-24 2011-08-23 pesticida 3-(fenil substituìdo)-5-(tienil ou furil)-1,2,4-triazóis, composição para controlar insetos ou ácaros, bem como processo para controlar insetos, ácaros, moscas brancas e afìdios, para proteger plantas de afìdios, ácaros ou insetos.
WO2000002871A1 (fr) 1998-07-10 2000-01-20 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
DE19858192A1 (de) 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
NZ520628A (en) 2000-01-18 2004-05-28 Vertex Pharma thiazole, oxazole, imdazole or pyrazole substituted pyrazole derivatives useful as treating bacterial infections
WO2002083667A2 (fr) 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases
DE60227794D1 (de) 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EA007933B1 (ru) 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
US20040198773A1 (en) 2001-09-26 2004-10-07 Barry Hart Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
WO2003027101A1 (fr) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 3-pyridyl pyrroles et 3-pyridyl pyrazoles substitues en tant qu'inhibiteurs de la lyase c17,20
EP1453789A2 (fr) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. Derives 1,3-diamino-2-hydroxypropane n-n'-substitues
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US20050004122A1 (en) 2002-08-14 2005-01-06 Brown Bradley B. Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP1708697A4 (fr) 2004-01-30 2007-11-28 Smithkline Beecham Corp Composes chimiques
RU2006138036A (ru) 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
CA2565965A1 (fr) 2004-05-06 2006-07-27 Plexxikon, Inc. Inhibiteurs de pde4b
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080045492A1 (en) 2004-12-21 2008-02-21 Coleman Paul J Mitotic Kinesin Inhibitors
EP1845973B1 (fr) 2005-01-21 2015-08-12 Astex Therapeutics Limited Composes pharmaceutiques
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
CN1834095B (zh) 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
PL1869049T3 (pl) 2005-03-21 2009-07-31 Lilly Co Eli Związki imidazopirydazyny
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
DE102005000046A1 (de) 2005-04-28 2006-11-02 Voith Patent Gmbh Maschine zur Herstellung einer Faserstoffbahn
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP2007197324A (ja) 2006-01-23 2007-08-09 Toray Ind Inc ２，４，５−置換−１，３−アゾール誘導体
HRP20130058T1 (hr) 2006-01-24 2013-02-28 Eli Lilly & Company Indolsulfonamidni modulatori progesteronskih receptora
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
KR20090008286A (ko) 2006-03-27 2009-01-21 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 피리딜- 및 피리미디닐-치환된 피롤-,티오펜- 및 푸란- 유도체
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Ｐｉ３ｋ저해제로 유용한 티에노［3,2-ｄ］피리미딘 유도체
WO2007129044A1 (fr) 2006-05-03 2007-11-15 Astrazeneca Ab Dérivés de thiazole et leur utilisation comme agents anti-tumoraux
JP2009538309A (ja) 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
WO2007138110A2 (fr) 2006-06-01 2007-12-06 Devgen N.V. Composés interagissant avec des canaux ioniques, notamment des canaux ioniques de la famille kv
WO2008001076A1 (fr) * 2006-06-26 2008-01-03 Ucb Pharma S.A. Dérivés de thiazole à cycle fusionnés en tant qu'inhibiteurs de kinase
WO2008011557A2 (fr) 2006-07-20 2008-01-24 Borchardt Allen J Inhibiteurs hétéroaryliques de la kinase rho
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008021235A2 (fr) 2006-08-14 2008-02-21 Schering Corporation Procédé et intermédiaires de synthèse de dérivés d'azole 2-(quinolin-5-yl)-4,5-disubstitués
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
WO2008023159A1 (fr) 2006-08-24 2008-02-28 Astrazeneca Ab Dérivés de la morpholino pyrimidine utiles dans le traitement de maladies prolifératives
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
ES2363178T3 (es) 2006-12-04 2011-07-26 Astrazeneca Ab Compuestos de urea policíclicos antibacterianos.
WO2008083070A1 (fr) 2006-12-29 2008-07-10 Neurogen Corporation Ligands des récepteurs du crf1 comprenant des groupes fonctionnels hétéroaryle bicycliques
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
ES2543325T3 (es) 2007-02-07 2015-08-18 Glaxosmithkline Llc Inhibidores de la actividad de Akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
WO2008157273A1 (fr) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Composés chimiques
WO2009006577A2 (fr) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
JP5736171B2 (ja) 2007-09-24 2015-06-17 ジェネンテック， インコーポレイテッド チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
WO2009049028A1 (fr) 2007-10-09 2009-04-16 Targegen Inc. Composés de pyrrolopyrimidine et leur utilisation en tant qu'inhibiteurs des janus kinases
WO2009094224A1 (fr) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophènes et leurs utilisations
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CL2009000780A1 (es) 2008-03-31 2010-01-15 Genentech Inc Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
GB0805818D0 (en) 2008-03-31 2008-04-30 Ucb Pharma Sa Therapeutic agents
KR20110018451A (ko) 2008-06-19 2011-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 티오펜 또는 티아졸 유도체, 그리고 ｐｉ3ｋ 저해물질로서 이들의 용도
JP2011525931A (ja) 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害剤
GB0812309D0 (en) 2008-07-03 2008-08-13 Ucb Pharma Sa Therapeutic agents
JP2011527680A (ja) 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
JP5698666B2 (ja) 2008-08-04 2015-04-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆａａｈの阻害剤として有用なオキサゾール誘導体
US8586582B2 (en) 2008-11-11 2013-11-19 Xcovery Holding Company, Llc PI3K/mTOR kinase inhibitors
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
WO2010080873A1 (fr) 2009-01-08 2010-07-15 Glaxo Group Limited Oxazoles en tant que modulateurs des récepteurs de la chimiokine
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (fr) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryles et applications associees
WO2010132598A1 (fr) 2009-05-13 2010-11-18 Amgen Inc. Composés hétéroaryle en tant qu'inhibiteurs des pikk
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
PH12013500274A1 (en) 2010-08-11 2013-03-04 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
WO2013096642A1 (fr) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci

Also Published As

Publication number Publication date
KR20140091462A (ko) 2014-07-21
US8765746B2 (en) 2014-07-01
MX2013004003A (es) 2013-10-01
AR083450A1 (es) 2013-02-27
JP2013542941A (ja) 2013-11-28
PH12013500723A1 (en) 2017-08-23
US20150148334A1 (en) 2015-05-28
SG189396A1 (en) 2013-05-31
CL2013001009A1 (es) 2013-08-30
CR20130204A (es) 2013-09-03
TW201307309A (zh) 2013-02-16
WO2012051410A2 (fr) 2012-04-19
EP2627181A2 (fr) 2013-08-21
EP2627181A4 (fr) 2014-03-19
DOP2013000082A (es) 2013-10-31
CA2814688A1 (fr) 2012-04-19
US20120214794A1 (en) 2012-08-23
ECSP13012621A (es) 2013-07-31
BR112013009166A2 (pt) 2016-07-26
PE20141044A1 (es) 2014-09-07
EA201390539A1 (ru) 2013-09-30
IL225607A0 (en) 2013-06-27
AU2011316016A1 (en) 2013-05-30
UY33671A (es) 2012-04-30
CO6801713A2 (es) 2013-11-29
WO2012051410A3 (fr) 2012-07-26
CN103237450A (zh) 2013-08-07

Similar Documents

Publication Publication Date Title
MA34652B1 (fr) Hétéroaryles et utilisations de ceux-ci
MA34797B1 (fr) Hétéroaryles et leurs utilisations
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MX2015005015A (es) Inhibidores heteroarilo de pde4.
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201790418A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
BR112015001695A2 (pt) compostos de heteroarila e heterociclo, composições e métodos
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
WO2013163190A8 (fr) Inhibiteurs d'adn pk
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201500362A1 (ru) Ингибиторы rho-киназы
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
PH12017500864A1 (en) Anti-notch1 antibodies
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
EA201290642A1 (ru) Соединения и способы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида